

**Original Paper****Clinicopathological changes associated with *Campylobacter jejuni* infection in broilers**Hamada H. El Azzy<sup>1</sup>, El Sayed Mansour<sup>1</sup>, Nsreen A. Shawky<sup>2</sup>, Mona Salh El Deen<sup>3</sup><sup>1</sup>Bacteriology Department, Animal Health Research Institute (Zagazig branches), Agriculture research center<sup>2</sup>Biochemistry Department, Animal Health Research Institute (Zagazig branches), Agriculture research center<sup>3</sup>Clinical Pathology Department, Animal Health Research Institute (Zagazig branches) Agriculture research center**ARTICLE INFO****Keywords**

Broiler  
*Campylobacter*  
 Hematobiochemical  
 Neomycin  
 Pefloxacin

Received 30/12/2020

Accepted 13/02/2021

Available On-Line  
01/04/2021**ABSTRACT**

The present study aimed to investigate the prevalence of *Campylobacter jejuni* and its clinicopathological changes in broiler chickens in Sharkia province. About 50 diarrheic broiler chicks' cloacal swabs were collected for bacteriological examination. Out of 50 examined swabs; 12 (24%) were positive for *Campylobacter* [4; *C. coli* 4 and 8; *C. jejuni*]. Isolated *Campylobacter* was sensitive to neomycin and gentamycin. About 45 healthy one-day-old broiler chicks received 5 mg pefloxacin/kg Bw for 5 days to exclude bacterial infections. At 14<sup>th</sup> day broilers were divided into 3 groups (15/ each). First group; healthy broilers non-treated (control), broilers in 2<sup>nd</sup> and 3<sup>rd</sup> groups were infected with *C. jejuni*. 2<sup>nd</sup> group were infected and non-treated, while 3<sup>rd</sup> group infected, and treated with 15 mg neomycin/kg Bw in drinking water for 5 days. At 1<sup>st</sup>, 7<sup>th</sup> and 14<sup>th</sup> day post treatment cloacal swabs were collected for re-isolation *C. jejuni* beside blood samples were collected for hematobiochemical study. Infected broilers showed off food, depression, ruffled feather, diarrhea and mortality rate 40% beside significant decrease in body performance, total protein albumin and non-significant decrease in globulin coupled with non-significant elevation in RBCs, HB, PCV%, significant elevation in WBCs, AST, ALT, ALP, urea and creatinine. Treatment infected broilers by neomycin lead to disappear clinical signs, reduced mortality rate and improved hematobiochemical parameters. It could be concluded that *Campylobacter* infection induces reversible adverse effect on body performance and hematobiochemical parameters. Neomycin is highly curative against *campylobacters*.

**1. INTRODUCTION**

Poultry has become an important source of meat in developing countries. Enteric disease in broilers is a common and important illness beside a risk for poultry industry in world (Kaakoush, et al. 2015). *Campylobacter* caused gastroenteritis is caused by two closely related species (*Campylobacter jejuni* and *Campylobacter coli*) but *Campylobacter jejuni* is the more predominant (Leonard, et al. 2020).

*Campylobacter* can appear in broilers as early as 14-day age at rearing with low percentage and increase to a high percentage at the end of grows out period (Evans, 2012). Most common routes of transmission are fecal-oral ingestion of contaminated food, water and eating of raw meat. Foods implicated in campylobacteriosis (Skarp, et al. 2016). *Campylobacter* infection is a wide range of avian spp. and rarely transmits vertically from parents to chicks (Huang, et al. 2017). *Campylobacter* cause diarrhea and health problem contributing substantially to childhood morbidity and mortality (Zhang, et al. 2018). *Campylobacters* are small and slender gram -ve spiral shaped rods beside its food and water-borne zoonotic diseases (Aneesa and Mohamed, 2019).

Antibiotics are used for bacterial infections (Thomrongsuwannakij, et al. 2018). *Campylobacteriosis* is treated by antibiotics as aminoglycoside which act by irreversible inhibition bacterial ribosomes and impairs protein synthesis of bacteria (Fernandes and Marten, 2017). Neomycin

is a member of aminoglycoside antibiotic against G +ve and G -ve organisms (Gupta and Plazomicin, 2017).

The aim of the present study was isolate, identify *Campylobacter* and its prevalence in broilers in Sharkia province beside its effect on body performance, hematochemical parameters with trail of treatment was studied.

**2. MATERIAL AND METHODS****2.1. Isolation and identification of *Campylobacter* spp**

About 50 diarrhoeic chicks' cloacal swabs were taken from different cities of Sharkia Province. Swabs were collected aseptically and inoculated into charcoal cefoperazone desoxycholate agar medium (selective medium for isolation of *Campylobacter*). Plates were incubated at 37°C for 72 hrs under special microaerophilic condition (85 % nitrogen 5% oxygen, 10% carbon dioxide) (Murray, et a. 2003). Suspected colonies were identified and Bio-typing by Gram staining, oxidase test, catalase test and standard biochemical methods (Atabay and Corry, 1997).

**2.2. Antibiotic sensitivity test (In vitro)**

Susceptibility of isolated *Campylobacter* species against different chemotherapeutic agents was tested by disc diffusion method (Quinn, et al. 1994).

\* Corresponding author: Hamada H. El Azzy, Bacteriology Department, Animal Health Research Institute (Zagazig branches), Agriculture research center

2.3. Antibacterial drugs

2.3.1. *Pefloxacin* (Peflodad 10 %) solution was obtained from Dar Al Dawa Vet and Agri Industrial Co. Itd Jordan. Each ml contains 100 mg of pefloxacin base.

2.3.2. *Neomycin sulphate* 20% produced from sento care Pharma comp Egypt

2.4. Experimental broilers and experimental design

About 45 apparently healthy one day-old Hubbard broilers nearly equal in live body weight (44.27-46.83gm) and received 5 mg pefloxacin/ kg bw in drinking water for 5 successive days for proving that broilers are free from any bacterial infections. Broilers were fed starter ration from Kahar Company and clean drinking water ad-libitum. At 14 day of age broilers were divided into three equal groups (15/each). Gp (1) healthy chicks (control), Broilers in Gp (2) were orally infected with 0.1ml saline containing(2.5×10<sup>8</sup> CFU) of isolated *C. jejuni*. Gp (2) infected broilers non treated and Gp (3) infected broilers, treated with 15 mg neomycin/kg Bw. in drinking water for 5 consecutive days.

2.5. Body weight:

Chicks were individually weighed at 1<sup>st</sup> day of age and at 1<sup>st</sup> day post treatment for estimation body weight gain and feed conversion rate

2.6. Re-isolation of *Campylobacter* spp.:

At 1<sup>st</sup>, 7<sup>th</sup> and 14<sup>th</sup> day posttreatmentcloacal swabs were collected for Re-isolation *Campylobacter jejuni*

2.7. Blood samples:

At 1<sup>st</sup>,7<sup>th</sup> and 14<sup>th</sup> day post treatment 2 blood samples were taken.

First sample was taken in a tube contain EDTA for estimation of blood picture Jain (1986).

Second sample was centrifuged to obtain clear serum for estimation of AST and ALT (Reitman and Frankel, 1957) ALP (John, 1982) total protein (Doumas, et al. 1981) albumin (Drupt 1974) globulin (mathematically). Uric acid (Artiss 1980) and creatinine (Henry, 1974).

2.8. *Statistical analysis* was performed by using analysis of variance (ANOVA). Duncan's Multiple Range Duncan, (1955) was used to determine differences among treatments mean at significance level of 0.05. Statistics were run using SPSS program (SPSS, 2004)

3. RESULTS

Examined cloaca swabs revealed 12 (24%) were positive for *Campylobacter* [4 *Campylobacter coli* and 8 *Campylobacter jejuni*].Both *Campylobacter coli*and *Campylobacter Jujuni* were negative for gram stain, positive oxidase and positive catalase and grow on 1% glycine, meanwhile *campylobacter coli* not hydrolysed Hippurate but *campylobacter Jujuni* hydrolysed Hippurate. (Table 1 and 2). Isolated *Campylobacter* was sensitive to neomycin and gentamycin (Table, 3). *Campylobacter jejuni* in broilers induced clinical signs (loss of appetite, depression, ruffled feather; diarrhea and 40% mortality rate at 1<sup>st</sup> and 7<sup>th</sup> day post treatment (Table 4). *Campylobacterjejuni* induced significant decrease ( $P < 0.5$ ) in body performance, total protein, albumin coupled with non-significant changes in globulin beside non-significant elevation in RBCs, HB, PCV% associated with significant increase in WBCs, AST, ALT, ALP, urea and creatinine at 1<sup>st</sup> and 7<sup>th</sup> day post treatment. Treatment infected broilers by neomycin showed disappear clinical sing, reduced mortality rate to 20%, not re-isolate *Campylobacter jejuni* and improved hematobiochemical parameters at 14<sup>th</sup> day post treatment (Table 4-8).

Table 1 Prevalence and type of isolated campylobacters

| Number of cloacal Swabs | -ve sample |    | +ve sample |    | Type of isolated campylobacters |       |                           |       |
|-------------------------|------------|----|------------|----|---------------------------------|-------|---------------------------|-------|
|                         | No         | %  | No         | %  | <i>Campylobacter jejuni</i>     |       | <i>campylobacter coli</i> |       |
|                         |            |    |            |    | No                              | %     | No                        | %     |
| 50                      | 38         | 76 | 12         | 24 | 8                               | 66.67 | 4                         | 33.33 |

Table 2 biochemical identification of *Campylobacter* spp in broiler chickens

| Positive cloacal swabs | <i>C. coli</i> (4) |          |         |                      | <i>C. Jujuni</i> (8) |            |          |         |                      |                      |
|------------------------|--------------------|----------|---------|----------------------|----------------------|------------|----------|---------|----------------------|----------------------|
|                        | Gram stain         | Catalase | Oxidase | Growth on 1% glycine | Hippurate hydrolysis | Gram stain | Catalase | Oxidase | Growth on 1% glycine | Hippurate hydrolysis |
|                        | -ve                | +        | +       | +                    | -                    | -ve        | +        | +       | +                    | +                    |
|                        |                    |          |         |                      |                      |            |          |         |                      |                      |

= GS. Catalase= cat. Oxidase=Ox. Growth on 1% glycine = GG. Hippurate hydrolysis= HH

Table3 Antibiotics sensitivity of *Campylobacter*.isolated from broilers to (n=5).

| Antibiotic    | Sample number | Sensitive |    | Moderate |    | Resistant |    |
|---------------|---------------|-----------|----|----------|----|-----------|----|
|               |               | No        | %  | No       | %  | No        | %  |
| Gentamycin    | 10            | 8         | 80 | 2        | 20 | 00        | 00 |
| Neomycin      | 10            | 6         | 60 | 4        | 40 | 00        | 00 |
| Ciprofloxacin | 10            | 7         | 70 | 3        | 30 | 00        | 00 |
| Erythromycin  | 10            | 7         | 70 | 3        | 30 | 00        | 00 |
| Tetracycline  | 10            | 4         | 40 | 6        | 60 | 00        | 00 |
| Ampicillin    | 10            | 00        | 00 | 2        | 20 | 8         | 80 |

Table 4 Mortality of healthy and diseased broilers and reisolated campylobacter

| Parameters Groups | Total No | Mortality rate |    | Reisolated of <i>Campylobacter</i> spp post treatment (day) |       |       |
|-------------------|----------|----------------|----|---|-------|-------|
|                   |          | No             | %  | 1   | 7     | 14    |
| Gp (1)            | 10       | 00             | 00 | 0.00  | 0.00  | 0.00  |
| Gp (2)            | 10       | 4              | 40 | 10/10   | 10/10 | 10/10 |
| Gp (3)            | 10       | 2              | 20 | 00/10   | 00/10 | 00/10 |

Table 5. Body performance of healthy and diseased broilers (n=5).

| Groups | Initial weight(1 <sup>st</sup> day of age) | Final weight (20 <sup>th</sup> day of age) | Weight gain              | FC     | FCR  |
|--------|--|--|--------------------------|--------|------|
| Gp (1) | 48.33±0.68 <sup>a</sup>                    | 951.16±1.33 <sup>b</sup>                   | 905.71±1.26 <sup>b</sup> | 990.45 | 1.07 |
| Gp (2) | 49.67±0.87 <sup>a</sup>                    | 946.32±1.46 <sup>c</sup>                   | 899.86±2.18 <sup>c</sup> | 980.85 | 1.09 |
| Gp (3) | 48.80±0.71 <sup>a</sup>                    | 966.14±4.13 <sup>a</sup>                   | 920.20±5.46 <sup>a</sup> | 990.71 | 1.04 |

FC=feed consumption. FCR= Feed Conversion rate. \* Significant at P < 0.05. Means with different superscripts of the same column indicate significant difference at P < 0.05

Table 6 RBCs, Hb, PCV and leukocytic count in healthy and diseased broilers (n=5.)

| Groups               | RBCs(10 <sup>9</sup> /μL) | Hb(g/dl)               | PCV%                    | WBCs (10 <sup>3</sup> / μL) |
|----------------------|---------------------------|------------------------|-------------------------|-----------------------------|
| 1 <sup>st</sup> day  | Gp (1)                    | 3.72±0.51 <sup>a</sup> | 13.80±1.93 <sup>a</sup> | 39.07±1.73 <sup>a</sup>     |
|                      | Gp (2)                    | 4.09±0.38 <sup>a</sup> | 14.69±1.60 <sup>a</sup> | 40.12±1.55 <sup>a</sup>     |
|                      | Gp (3)                    | 4.21±0.39 <sup>a</sup> | 14.89±1.33 <sup>a</sup> | 40.56±1.40 <sup>a</sup>     |
| 7 <sup>th</sup> day  | Gp (1)                    | 3.61±0.43 <sup>a</sup> | 13.77±1.82 <sup>a</sup> | 39.11±1.57 <sup>a</sup>     |
|                      | Gp (2)                    | 4.06±0.50 <sup>a</sup> | 14.54±1.54 <sup>a</sup> | 40.17±1.43 <sup>a</sup>     |
|                      | Gp (3)                    | 4.18±0.43 <sup>a</sup> | 14.68±1.24 <sup>a</sup> | 40.24±1.36 <sup>a</sup>     |
| 14 <sup>th</sup> day | Gp (1)                    | 3.75±0.47 <sup>a</sup> | 13.76±1.68 <sup>a</sup> | 39.12±1.56 <sup>a</sup>     |
|                      | Gp (2)                    | 4.17±0.33 <sup>a</sup> | 14.60±1.69 <sup>a</sup> | 40.17±1.50 <sup>a</sup>     |
|                      | Gp (3)                    | 4.33±0.34 <sup>a</sup> | 14.85±1.28 <sup>a</sup> | 40.49±1.37 <sup>a</sup>     |

Means with different superscripts of the same column indicate significant difference at P < 0.05

Table 7 Protein profile (g/dl) in healthy and diseased broilers (n=5).

| Groups               | T.Protein | Albumin                | Globulin               | A/G ratio              |
|----------------------|-----------|------------------------|------------------------|------------------------|
| 1 <sup>st</sup> day  | Gp(1)     | 5.06±0.13 <sup>a</sup> | 2.69±0.19 <sup>a</sup> | 2.37±0.11 <sup>a</sup> |
|                      | Gp(2)     | 4.62±0.12 <sup>b</sup> | 1.86±0.21 <sup>b</sup> | 2.16±0.12 <sup>a</sup> |
|                      | Gp(3)     | 4.47±0.21 <sup>b</sup> | 2.02±0.16 <sup>b</sup> | 2.01±0.17 <sup>a</sup> |
| 7 <sup>th</sup> day  | Gp(1)     | 5.90±0.50 <sup>a</sup> | 2.82±0.22 <sup>a</sup> | 2.11±0.10 <sup>a</sup> |
|                      | Gp(2)     | 4.60±0.68 <sup>b</sup> | 2.38±0.47 <sup>b</sup> | 2.01±0.08 <sup>a</sup> |
|                      | Gp(3)     | 6.46±0.36 <sup>a</sup> | 3.50±0.28 <sup>a</sup> | 2.06±0.17 <sup>a</sup> |
| 14 <sup>th</sup> day | Gp(1)     | 5.87±0.55 <sup>a</sup> | 2.78±0.24 <sup>a</sup> | 2.07±0.14 <sup>a</sup> |
|                      | Gp(2)     | 4.55±0.70 <sup>a</sup> | 2.35±0.56 <sup>a</sup> | 2.20±0.25 <sup>a</sup> |
|                      | Gp(3)     | 6.76±0.41 <sup>a</sup> | 3.60±0.44 <sup>a</sup> | 3.06±0.39 <sup>a</sup> |

Means with different superscripts of the same column indicate significant difference at P < 0.05

Table 8 Liver enzymes and kidney functions in healthy and diseased broilers (n=5)

| Groups               |        | liver enzymes (U/L)     |                         |                         | Kidney functions (mg/dl) |                        |
|----------------------|--------|-------------------------|-------------------------|-------------------------|--------------------------|------------------------|
|                      |        | AST                     | ALT                     | ALP                     | Uric acid                | creatinine             |
| 1 <sup>st</sup> day  | Gp (1) | 89.04±1.46 <sup>b</sup> | 56.16±1.02 <sup>b</sup> | 40.95±0.90 <sup>b</sup> | 4.74±0.29 <sup>b</sup>   | 1.06±0.09 <sup>c</sup> |
|                      | Gp (2) | 94.33±1.21 <sup>a</sup> | 59.97±1.25 <sup>a</sup> | 44.17±0.78 <sup>a</sup> | 6.14±0.28 <sup>a</sup>   | 1.72±0.21 <sup>a</sup> |
|                      | Gp (3) | 92.99±1.01 <sup>a</sup> | 58.52±1.04 <sup>a</sup> | 43.08±0.17 <sup>a</sup> | 5.49±0.14 <sup>a</sup>   | 1.30±0.10 <sup>b</sup> |
| 7 <sup>th</sup> day  | Gp (1) | 88.99±1.39 <sup>b</sup> | 56.13±0.98 <sup>b</sup> | 40.89±0.94 <sup>b</sup> | 4.73±0.27 <sup>b</sup>   | 1.02±0.08 <sup>b</sup> |
|                      | Gp (2) | 93.97±1.15 <sup>a</sup> | 59.91±1.14 <sup>a</sup> | 44.21±0.69 <sup>a</sup> | 6.11±0.21 <sup>a</sup>   | 1.70±0.20 <sup>a</sup> |
|                      | Gp (3) | 91.43±1.32 <sup>b</sup> | 57.35±1.35 <sup>b</sup> | 41.56±0.89 <sup>b</sup> | 5.40±0.16 <sup>a</sup>   | 1.34±0.12 <sup>a</sup> |
| 14 <sup>th</sup> day | Gp (1) | 89.08±1.42 <sup>b</sup> | 56.15±1.04 <sup>b</sup> | 40.92±0.89 <sup>b</sup> | 4.70±0.31 <sup>b</sup>   | 1.63±0.25 <sup>b</sup> |
|                      | Gp (2) | 93.68±1.30 <sup>a</sup> | 59.83±1.02 <sup>a</sup> | 44.34±0.71 <sup>a</sup> | 6.17±0.25 <sup>a</sup>   | 2.64±0.2 <sup>a</sup>  |
|                      | Gp (3) | 90.75±1.19 <sup>b</sup> | 57.10±1.85 <sup>b</sup> | 41.23±0.88 <sup>b</sup> | 5.44±0.21 <sup>b</sup>   | 1.77±0.19 <sup>b</sup> |

Means with different superscripts of the same column indicate significant difference at P < 0.05

#### 4. DISCUSSION

Infected bird with *Campylobacter* carry a very high bacterial concentration in their gastrointestinal tract and the main sites of colonization of *Campylobacter* in poultry are the caeca, colon and cloaca (Facciola, et al. 2017). *Campylobacter* infection is characterized by inflammatory, sometimes bloody diarrhea or dysentery syndrome (cramps, fever, and pain) (Liz, et al. 2020).

In the current study, the prevalence of campylobacter was 24%. Our results are in agreement with Khalifa, et al. (2011) who observed that the prevalence of *Campylobacter* in broilers in Kaliobia was 26%. *Campylobacter* prevalence in broilers from Sharkia Province was 29.3% (Ashraf, et al. 2018). The prevalence of *Campylobacter* in Assuit Province was 21.5% (Mostafa, et al. 2018) in broilers. Variation in *Campylobacter* prevalence may be due to difference in sanitation (Leonard, et al. 2020).

In the present study, *Campylobacter* isolates were identified as *Campylobacter jejuni* 8 (66.67%) and *Campylobacter coli* 4 (33.33%). Same results were reported by Saad (2014) who identified *Campylobacter jejuni* in rate

of 60.9% in Sharkia Province. Comparable percentages of *Campylobacter jejuni* 56% were reported by Abd El-Tawab et al. (2015) in Sharkia Province. Identified *Campylobacter jejuni* in rate of 66% in Egypt (Ashraf, et al. 2018)

Disc diffusion test revealed isolated *Campylobacter* was sensitive to neomycin and gentamycin. *Campylobacter* isolated from broilers was sensitive to neomycin and gentamycin (Sayed 2000).

Our obtained results revealed that infected broilers with *Campylobacter jejuni* showed clinical signs (ruffled feather, depression, loss of appetite, diarrhea, reduction in body weights and mortality rate was 40%). Diseased broilers treated with neomycin showed disappearance of clinical signs and reduction in mortality rate to 20 % and not re-isolate *Campylobacter jejuni*. Same clinical signs were observed by Khalil (2002) in broilers infected with *Campylobacter jejuni*. This result was consistent with Liz, et al. (2020) who stated that broilers infected with *Campylobacter jejuni* showed loss of appetite, depression, diarrhea, and reduction in body weights. Neomycin is a very effective drug against *Campylobacter jejuni* as it caused

disappearance of clinical signs and decreased mortality rate in chickens (Krishna, et al. 2018).

Our results revealed that, broilers infected with *Campylobacter jejuni* showed non-significant change in RBCs, Hb, PCV % and significant increase in WBCs. Leukocytosis in infected broiler may be due to inflammatory response in intestinal tract (Radostitis, et.al. 2002). Similar result in blood picture was observed by Thrall (2004) stated that broilers infected with *Campylobacter* showed non-significant elevation in RBCs, Hb, PCV% and significant leukocytosis. *Campylobacter* induce significant elevation in leukocytic count in broilers (Lavini, et al. 2016).

In the present study, *campylobacter* infection induced significant decrease in total proteins, albumin and non-significant decrease in globulin. Reduction in total protein and albumin in broiler infected with *campylobacter* may be due to liver damage by *campylobacter* toxins in which liver is the sole site of albumin synthesis (Latimer, et al. 2003). Hypoalbuminemia in infected broilers may be due to inappetance and male absorption of nutrients from inflamed intestine (Thrall,2004). *Campylobacter* induce decrease in in total protein and albumin in chickens (Lavini, et al. 2016).

Our results showed that, broilers suffering from campylobacteriosis showed significant increase in AST, ALT, ALP, uric acid and creatinine. Elevation of liver enzyme, uric acid and creatinine comes from Radostitis, et.al. (2002) stated that *campylobacter* toxins induced degenerative changes and necrotic processes in liver and kidneys leading to increase in liver enzymes, uric acid and creatinine. These results were confirmed by result recorded by Lavini, et al. (2016) who stated that with *campylobacter jejuni* showed increase in liver enzymes, uric acid and creatinine in broilers

Our study revealed that, treatment *campylobacters* in broilers using neomycin resulted in disappearance of clinical signs, reduction in mortality rate up to (10%), improved in body weight and not re-isolate *campylobacter* beside improved in hemato-biochemical parameters to normal level at 14<sup>th</sup> day post treatment. Same result were reported previously by Hassanain, (2011) in broilers infected with *campylobacter* and treated with neomycin. Our results were reinforced by Agnes, et al. (2012) who observed an improvement in broilers infected with *campylobacter* and treated with neomycin.

## 5. CONCLUSIONS

It could be concluded that *Campylobacter jejuni* induce many changes in haemato-biochemical parameters in broilers but neomycin in therapeutic dose was effective in medication of *campylobacters* infection in broiler chickens.

## 6. REFERENCES

- Abd El-Tawab, A.; Ammar, A.; Ahmed, H.; and Hefny, A. (2015) Bacteriological and Molecular Identification of *Campylobacter* spp in Chickens and Humans at Zagazig City, Egypt. *Benha Vet. Med. J.* 28, 17-26
- Aneesa, N. and Mohamed K (2019) Prevalence and Antimicrobial Susceptibility of *Campylobacter* spp. in Poultry. *The Open Microbiology J.* 13,124-132
- Agnes, A.; Dave, L. and Carolee, C. (2012) Review of antimicrobial therapy of selected bacterial diseases in broilers in Canada. *Can Vet J.* 53(12)289-300
- Artiss J (1980) determination of uric acid. *Clin. Chem. Acta* (116) 30-39
- Ashraf A.; Ahmed A.; Heba A; Fatma I and Ahmed A (2018) Bacteriological and Molecular Identification of some *Campylobacter* Species in Broilers and their Macrolide Resistance Profile. *Benha Vet. Med. J.* 34(1) 374 - 391
- Atabay, H and Corry, J (1997) the isolation and prevalence of *Campylobacter* from the dairy using a variety of methods. *J. App. Microb.*, 84: 33-40.
- Doumas B, Cartor R, Peers T and Schaffier R (1981) A candidate reference method for determination T. protein in serum *Clin Chem.* 27, 1642
- Drupt F (1974): determination of albumin. *Phar. Bio.9*
- Duncan, D. (1955): Multiple ranges and multiple "F" test. *Biometrics*, 11:10.
- Evans, S. (2012) Introduction and spread of thermophilic *campylobacters* in broiler flocks, *The Veterinary record*, 2012, 151, 574-576
- Facciola, A., Riso, R.; Visalli, G. and Lagana, P. (2017) *Campylobacter*: from microbiology to prevention. *J. Prev. Med. Hyg* 58: 79-92
- Fernandes, P. and Martens, E. (2017) Antibiotics in late clinical development. *Biochemical Pharmacology*; 133:152-163
- Gupta, A and Plazomicin, A (2017) step toward next generation aminoglycosides. *Review. Asian J. of Res. in Pharmaceutical Sci.*; 7(3):1-8
- Hassanain, N. (2011) Antimicrobial Resistant *Campylobacter jejuni* isolated from humans and animals in Egypt. *Global Veterinaria* 6(2)195-200
- Henry R (1974) Colorimetric determination of creatinine. *Clinical chemistry, principles and technics*, 2<sup>nd</sup> Ed., Harper and Row, P. 525.
- Huang, J; Lei, T and Jiao, X(2017) Quantitative analysis of *Campylobacterspp* contamination in chicken slaughtering line in China. *Food Cont* 80:67-73
- Jain N (1986) Schalm's Vet Haematology, 4<sup>th</sup> Ed Fibiger, Philadelphia, USA
- Joan, F. and Pannal, P. (1981): *Clinical chemistry in diagnosis and treatment*. 3<sup>rd</sup> Ed. Liayed-Luke, London.
- John D (1982) laboratory method for determination ALP 9<sup>th</sup> Ed. 580-81
- Kaakoush N; Castano, N; Mitchell, H and Man, S (2015) Global epidemiology of *Campylobacter* infection. *Clin Microbiol Rev.* 28: 687-720.
- Khalil, M. (2002): *Studies on campylobacters in ducks*. M.V.Sc. D. Thesis, Fac of Vet. Med. Moshtohor, Zag. Uni, Benha Branch.
- Khalifa, N.; Radwan, E and Sobhy, M (2011) molecular study of *campylobacter jejuni* isolated from chicken, dairy cattle and human to determine their zoonotic importance *Amer J of Res Comm.* 43(3) 229-239
- Krishna, P.; Charlotte, L.; Ricarda, M.; Radhika, V.; Marta, K.; André, C. and Ewa, S. (2018) Influence of silver nanoparticles on growth and health of broiler chickens after infection with *Campylobacter jejuni*. *BMC Vet. Res.* 14 (1) 231-242
- Latimer K, Mahaley E and Prasse K (2003): *Duncan and Prasse's Laboratory Vet Med and Clinical Pathology*. 4<sup>th</sup> Ed, Iowa state Uni. press. Ames. Iowa USA.
- Lavini, S.; Calin, J. and Nicolae, C. (2016) Evaluation of administration effects of probiotics against *campylobacter jejuni* on the immune system of broiler chickens. *Animal Sci. and Biotechnologies*, 49 (1) 213-225
- Leonard, E.; Mecky, I.; Dieudonné, M. and Erick, V. (2020) Prevalence and antimicrobial resistance profiles of *Campylobacter Spp* in humans and animals in Sub-Saharan Africa: Systematic Review. *Inter J. of Micro*, 123-146
- Liz, J; Rhiannon, L; Martyd, K and Kathr, Y (2020) Prevalence of *Campylobacter coli* and *Campylobacter jejuni* in Retail chicken, Beef, Lamb, and Pork Products in Three Australian States. *J Food Prot* 82 (12) 26-34.
- Mostafa, F.; Awad, A. and Hanan, A. (2018) Prevalence of *Campylobacter* in Chicken and Humans in Assiut province. *Appro Poult and Vet Sci* 3(4)1-9
- Murray, P, Baron, E and Nahmakin, J (2003) *Campylobacter* in Manual of Clinical Microbiology. Washington, D: American Soc for Micro. Press:5:90-91

30. Quinn P., Carte M., Markeryo B and Carter G (1994) Clinical Veterinary. Microbiology Year book-wolf publishing-Europe Limited.
31. Radostitis, O.; Blood, D. and Gay, C. (2002): Veterinary Medicine, 10<sup>th</sup> Ed, PP.1343, Bailliere Tindall, London, Tokyo and Philadelphia
32. Reitman S and Frankel S (1957) Calorimetric determination of transaminaeses activity Am. J. Clin. Path .28:56
33. Saad, A (2014) Zoonotic Importance of campylobacteriosis at Sharkia Province. Master thesis Zoonoses Department, Faculty of Vet. Med Zag Univ Egypt
34. Sayed, M. (2000) Campylobacter Infection in Broiler Chickens in Assiut. Assiut Vet. Med. J. 42 (84) 55-64
35. Shih, D. (2000) Isolation and identification of enteropathogenic *Campylobacter* spp. from chicken samples in Taipei. J. of food protection 63, 304-308.
36. Sarp, C.; Hanninen, M. and Rautelin, H. (2016) Campylobacteriosis: the role of poultry meat. Clin Microbiol Infect. 22:103–9.
37. SPSS (2004):"Statistical and package for social sci., SPSS for windows release." Standard version, copyright SPSS Inc1989-2004.
38. Thomrongsuwannakij, T.; Blackall, P. and Chansiripornchai, N. (2018) A Study on *Campylobacter jejuni* and *Campylobacter coli* through commercial broiler production chains in thailand: Avian Dis.; 62(2)86-99.
39. Thrall, M. (2004) Veterinary Hematology and Clinical Chemistry. Lippincott Williams and Wilins, Maryland, USA.
40. Zhang, X.; Tang, M. and Gao, Y. (2018) characteristics of *Campylobacter* during slaughter process of different broiler batches. Front Micro.9:292-299